微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 20.23% | 108.27% | 19.59% | 140/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 16.92% | -15.39% | -0.78% | 140/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 17.05% | -28.17% | 7.82% | 139/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 15.81% | -40.14% | 62.78% | 141/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 9.71% | -66.12% | -51.41% | 141/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 19.99% | -22.72% | -15.76% | 134/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 23.73% | -22.37% | -10.16% | 130/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 26.42% | -18.18% | -7.85% | 123/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 28.67% | -1.5% | 10.82% | 118/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 25.87% | -21.45% | -15.39% | 127/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 30.57% | 2.64% | -5.3% | 118/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 32.28% | 15.4% | 10.93% | 115/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 29.1% | 6.1% | -11.63% | 118/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 32.94% | 43.8% | 10.57% | 114/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 29.79% | 8.34% | 6.48% | 110/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 27.97% | 5.27% | 1.99% | 123/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 27.43% | 24.53% | 19.76% | 115/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 22.9% | -24.62% | -16.69% | 138/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 27.49% | -12.23% | 3.46% | 118/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 26.57% | -19.92% | 20.65% | 128/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 22.03% | 45.51% | -27.51% | 118/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 30.38% | 30.64% | -3% | 125/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 31.32% | 43.36% | -5.61% | 103/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 33.18% | 62.14% | 119.22% | 110/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 15.14% | -24.01% | -34.91% | 106/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 23.26% | -33.2% | 6.44% | 126/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 21.85% | -42.42% | 6.76% | 100/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 20.47% | -45.53% | 2.74% | 107/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 19.92% | -50.98% | -42.78% | 99/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 34.82% | -4.57% | -8.24% | 103/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 37.94% | 5.16% | 0.98% | 76/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 37.58% | 18.77% | -7.54% | 80/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 40.64% | 42.85% | 11.4% | 70/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 36.48% | 42.2% | 1.11% | 86/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 36.08% | 43.29% | 14.05% | 67/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 31.64% | 24.63% | 11.21% | 75/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 28.45% | 8.22% | 10.89% | 64/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 25.66% | 44.68% | 1.88% | 97/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 25.18% | 37.23% | -0.8% | 70/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 25.39% | 47.02% | -3.44% | 76/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 26.29% | 47.63% | 48.24% | 64/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |